ATE473965T1 - Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität - Google Patents

Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität

Info

Publication number
ATE473965T1
ATE473965T1 AT05807786T AT05807786T ATE473965T1 AT E473965 T1 ATE473965 T1 AT E473965T1 AT 05807786 T AT05807786 T AT 05807786T AT 05807786 T AT05807786 T AT 05807786T AT E473965 T1 ATE473965 T1 AT E473965T1
Authority
AT
Austria
Prior art keywords
radioactively labeled
receptor functionality
based ligands
quinoline
labeled quinoline
Prior art date
Application number
AT05807786T
Other languages
English (en)
Inventor
Antony David Gee
Laurent Martarello
Christopher Norbert Johnson
David R Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE473965T1 publication Critical patent/ATE473965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AT05807786T 2004-11-19 2005-11-17 Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität ATE473965T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0425548.5A GB0425548D0 (en) 2004-11-19 2004-11-19 Radiolabelled ligands
PCT/EP2005/012463 WO2006053785A1 (en) 2004-11-19 2005-11-17 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality

Publications (1)

Publication Number Publication Date
ATE473965T1 true ATE473965T1 (de) 2010-07-15

Family

ID=33548578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05807786T ATE473965T1 (de) 2004-11-19 2005-11-17 Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität

Country Status (7)

Country Link
EP (1) EP1824830B1 (de)
AT (1) ATE473965T1 (de)
CA (1) CA2588381A1 (de)
DE (1) DE602005022346D1 (de)
ES (1) ES2348285T3 (de)
GB (1) GB0425548D0 (de)
WO (1) WO2006053785A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP2120950B1 (de) * 2007-03-21 2012-07-04 Glaxo Group Limited Verwendung von chinolin-derivaten zur behandlung von schmerzen
DE602007012683D1 (de) * 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
AU2008285652B2 (en) 2007-08-07 2013-09-05 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
HRP20150560T2 (hr) 2010-11-10 2015-11-20 H. Lundbeck A/S Radiooznaäśeni ligandi na bazi fenilimidazola
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
US20130343993A1 (en) * 2012-01-06 2013-12-26 Abbvie Inc. Radiolabeled 5-ht6 ligands
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
US12655150B2 (en) 2021-03-26 2026-06-16 Cedilla Therapeutics, Inc. TEAD inhibitors and uses thereof
WO2022272036A1 (en) * 2021-06-25 2022-12-29 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60309852T2 (de) * 2002-03-27 2007-06-06 Glaxo Group Ltd., Greenford Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
GB0425548D0 (en) 2004-12-22
EP1824830A1 (de) 2007-08-29
CA2588381A1 (en) 2006-05-26
WO2006053785A1 (en) 2006-05-26
DE602005022346D1 (de) 2010-08-26
EP1824830B1 (de) 2010-07-14
ES2348285T3 (es) 2010-12-02

Similar Documents

Publication Publication Date Title
DE602005022346D1 (de) Radioaktiv markierte liganden auf chinolinbasis für die 5-ht6-rezeptorfunktionalität
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
EA200702619A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
BRPI0410711A (pt) novos compostos
ATE338743T1 (de) Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)
DE602006019822D1 (de) Reines rocuroniumbromid
NO20083207L (no) Inhibitorer av IAP
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
MA30780B1 (fr) Composes et procedes associes a des agents etiquetes 18f
EP2216651A4 (de) Biomarker zur diagnose einer lebererkrankung
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
EP2365974A4 (de) Fluorierte benzothiazolderivate, verfahren zu deren herstellung und bilddarstellendes mittel für die diagnose von alzheimer-krankheit, welches diese verwendet
NO20072974L (no) Fenylpiperazinderivater med en kombinasjon av partiell dopamin-D2-receptoragonisme og serotoningjenopptaksinhibering
MA31623B1 (fr) Nouveaux herbicides
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
BR0211140A (pt) Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
DE69906101D1 (de) 3-bicycloindole als liganden des 5-ht 1d rezeptors
ATE549316T1 (de) Piperidinderivate als nk3-rezeptorantagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties